| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding | |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | Entrez:608 MIM:109545 HGNC:HGNC:11913 Ensembl:ENSG00000048462 AllianceGenome:HGNC:11913 | |
| Description | TNF receptor superfamily member 17 | |||||
| Gene symbol | PDCD1 | Synonyms | CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 | Type of gene | protein-coding | |
| Chromosome | 2 | Map location | 2q37.3 | dbXrefs | Entrez:5133 MIM:600244 HGNC:HGNC:8760 Ensembl:ENSG00000188389 AllianceGenome:HGNC:8760 | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | |||||
| Description | programmed cell death 1 | |||||
| GTO ID | GTC2245 |
| Trial ID | NCT04162119 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA|PD1 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BCMA/PD1 CAR-T cells |
| Phase | Phase2 |
| Recruitment status | Unknown |
| Title | Safety and Efficiency Study of BCMA-PD1-cells in Relapsed/Refractory Multiple Myeloma |
| Year | 2019 |
| Country | China |
| Company sponsor | Chinese PLA General Hospital |
| Other ID(s) | HNYY-XYK-01 |
| Cohort 1 | |||||||
|
|||||||